CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted FCF Margin of 7503.5% for Q1 2026, up 30.34% sequentially from 10771.99% in Q4 2025, and down 124304.0% YoY from N/an in Q1 2025.
CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported FCF Margin for 11 years, with the latest figure at 7503.5% in Q1 2026.
- Quarterly FCF Margin fell 124304.0% year-over-year to 7503.5% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9777.63% (down 896512.0% YoY) and the FY2025 annual result came in at 9855.5%, down 947246.0% from the prior year.
- FCF Margin improved to 7503.5% in Q1 2026 per CRSP's latest filing, from 10771.99% in the prior quarter.
- Over five years, FCF Margin peaked at 21633.13% in Q1 2024 and troughed at 1842166.67% in Q4 2022.
- A 5-year average of 131981.19% and a median of 10150.22% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 184142846 bps in 2022, then surged 184211893 bps in 2023.
- Over 5 years, FCF Margin stood at 1842166.67% in 2022, then soared by 100 bps to 47.73% in 2023, then sank by 185 bps to 136.0% in 2024, then sank by 7821 bps to 10771.99% in 2025, then surged by 30 bps to 7503.5% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 7503.5%, 10771.99%, and 9528.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -826.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -826.50% |
| Mar 31, 2026 | -7,503.50% |
| Dec 31, 2025 | -10,771.99% |
| Sep 30, 2025 | -9,528.46% |
| Jun 30, 2025 | -12,779.93% |
| Mar 31, 2025 | -6,260.46% |
| Dec 31, 2024 | -136.00% |
| Sep 30, 2024 | -17,796.01% |
| Jun 30, 2024 | -18,624.56% |
| Mar 31, 2024 | 21,633.13% |
| Dec 31, 2023 | -47.73% |
| Jun 30, 2023 | -187.45% |
| Mar 31, 2023 | 5.74% |
| Dec 31, 2022 | -1,842,166.67% |
| Sep 30, 2022 | -90,592.55% |
| Jun 30, 2022 | -101,929.11% |
| Mar 31, 2022 | -15,013.51% |
| Dec 31, 2021 | -738.20% |
| Sep 30, 2021 | -14,366.26% |
| Jun 30, 2021 | 86.64% |